TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02722304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARALAST NP 60 mg/kg
Description: ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARALAST NP 120 mg/kg
Description: ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA 60 mg/kg
Description: GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA 120 mg/kg
Description: GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human Albumin 2%
Description: Human albumin 2% (by appropriate dilution with normal saline solution)
Study: NCT05304325

Intervention type: OTHER
Intervention: Food intake
Description: Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
Study: NCT02215356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
Study: NCT02615639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPDC-T cells & Entecavir
Description: experimental groups will be given HPDC-T cells \& Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5mg tablet every night by mouth
Study: NCT00958074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study: NCT02615639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPDC-T cells & IFN-a-2a
Description: experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
Study: NCT00958074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: correlative study
Study: NCT02615639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN-a-2a
Description: IFN-a-2a 180ug subcutaneous injection every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPDC-T cells & Telbivudine
Description: experimental groups will be given HPDC-T cells \& Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Description: Telbivudine 600mg tablet every day by mouth
Study: NCT01545505

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test.
Study: NCT04928859

Intervention type: DRUG
Intervention: Albumin
Description: At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group.~The patients who have no albumin use during their hospitalization in the burn ward consisted the control group.
Study: NCT00958074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study
Study: NCT04345224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic tape
Description: A kinesiology tape will be applied to the lateral hip of the affected side to facilitate the gluteus medius muscle activation while the participant is lying down. The first third of one I-strip will begin at the posterior iliac crest without tension to provide an anchor that will not cross the target tissue. The participant will actively flex the adducted hip to allow for the application of the middle third of the tape with approximately 50 percent tension (able to visualize the wave pattern in the tape). Subsequently, with the leg in the original position, the remainder of the tape will be applied without tension, ending approximately at the greater trochanter. Afterward, the second I-strip will be applied in the same manner starting at the anterior iliac crest.
Study: NCT01537562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of IUC insertion
Description: Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
Study: NCT04345224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid tape
Description: The rigid tape will be applied in a standing position. The first tape will be applied from the greater trochanter to the anterior iliac crest. The second from the greater trochanter to the posterior iliac crest. Both tapes are applied with the muscle mass lifted towards the iliac crest.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tape
Description: The control group (sham tape application) will receive a single strip of a Kinesio tape across the lateral affected hip without tension in the tape or muscle stretch.
Study: NCT04381715

Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study: NCT01244659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus from EMS
Description: Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Study: NCT00989885

Intervention type: OTHER
Intervention: Questionnaire and polysomnography
Description: Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
Study: NCT03675906

Intervention type: OTHER
Intervention: hypoalbuminemia
Description: hypoalbuminemia and acute kidney injury

Intervention type: OTHER
Intervention: hypoalbuminemia
Description: hypoalbuminemia and acute kidney injury
Study: NCT00968162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
Study: NCT01829347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD
Description: ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
Study: NCT03675906

Intervention type: OTHER
Intervention: hypoalbuminemia
Description: hypoalbuminemia and acute kidney injury
Study: NCT00947180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
Study: NCT01829347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care treatment
Description: Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
Study: NCT03099278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 20 mg oral daily
Study: NCT00947180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrogalvanic stimulation
Description: Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital massage
Description: Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
Study: NCT02813694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lefamulin
Description: antibacterial agent
Study: NCT01766258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-101 65mg Carbidopa
Study: NCT01829347

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care treatment
Description: Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
Study: NCT04298385

Intervention type: OTHER
Intervention: Traction orthosis
Description: Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
Study: NCT02136381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP intervention
Description: LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months.
Study: NCT01482832

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal therapy-based treatment
Description: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
Study: NCT01766258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-101 105mg Carbidopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stalevo
Study: NCT01482832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy-based treatment
Description: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
Study: NCT03005899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB P-1501
Description: After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed
Study: NCT03456323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
Study: NCT02924155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP002
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Study: NCT04649424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CanSwab
Description: New nasopharyngeal swab design.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CanSwab
Description: New nasopharyngeal swab design.
Study: NCT03005899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SyB P-1501 placebo
Description: Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
Study: NCT04173494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablets will be self-administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match danazol
Description: Danazol placebo capsules will be self-administered orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Danazol capsules will be self-administered orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match momelotinib
Description: Momelotinib placebo tablets will be self-administered orally once daily
Study: NCT01599988

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caseinate
Description: The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Protein Isolate
Description: The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
Study: NCT03448913

Intervention type: PROCEDURE
Intervention: PECS block
Description: It consists in injection of 20-30 ml of local anesthetic between pectoral minor, pectoral major, and serratus muscles.
Study: NCT01608594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of ipilimumab10mg/kg
Description: Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of ipilimumab 3mg/kg + HDI
Description: Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
Study: NCT01416038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Vaccine targeting survivin antigen will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Vaccine targeting survivin antigen will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Vaccine targeting survivin antigen will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose cyclophosphamide (oral)
Description: Low dose cyclophosphamide will be taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose cyclophosphamide (oral)
Description: Low dose cyclophosphamide will be taken by mouth.
Study: NCT03104413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab IV
Description: placebo for risankizumab administered as intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab administered by subcutaneous (SC) injection
Study: NCT02952443

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).

Intervention type: BEHAVIORAL
Intervention: Control
Description: The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
Study: NCT01790997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: 1 tablet of DLBS1033 490 mg thrice daily, after meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 1 tablet of aspirin 80 mg once daily, after meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 1 tablet of clopidogrel 75 mg once daily, after meal
Study: NCT04090801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil 5% in 90% ethanol and 5% propylene glycol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil 5% in pure ethanol alone
Description: The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Ethanol)
Description: The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.